Search

Your search keyword '"Neville, A.M."' showing total 97 results
Start Over Author "Neville, A.M."
97 results on '"Neville, A.M."'

3. Cancer-testis antigen expression in triple-negative breast cancer

Author

Curigliano, G., Viale, G., Ghioni, M., Jungbluth, A. A., Bagnardi, V., Spagnoli, G. C., Neville, A.M., Nolè, F., Rotmensz, N., Goldhirsch, A., Curigliano, G., Viale, G., Ghioni, M., Jungbluth, A. A., Bagnardi, V., Spagnoli, G. C., Neville, A.M., Nolè, F., Rotmensz, N., and Goldhirsch, A.

Abstract

Background: Cancer-testis (CT) antigens, frequently expressed in human germline cells but not in somatic tissues, may become aberrantly reexpressed in different cancer types. The aim of this study was to investigate the expression of CT antigens in breast cancer. Patients and methods: A total of 100 selected invasive breast cancers, including 50 estrogen receptor (ER) positive/HER2 negative and 50 triple negative (TN), were examined for NY-ESO-1 and MAGE-A expression by immunohistochemistry. Results: A significantly higher expression of MAGE-A and NY-ESO-1 was detected in TN breast cancers compared with ER-positive tumors (P = 0.04). MAGE-A expression was detected in 13 (26%) TN cancers compared with 5 (10%) ER-positive tumors (P = 0.07). NY-ESO-1 expression was confirmed in nine (18%) TN tumor samples compared with two (4%) ER-positive tumors. Conclusions: MAGE-A and NY-ESO-1 CT antigens are expressed in a substantial proportion of TN breast cancers. Because of the limited therapeutic options for this group of patients, CT antigen-based vaccines might prove to be useful for patients with this phenotype of breast cancer

Published
2017

5. Micrometastases in Breast Cancer

Author

COOMBES, R.C., primary, DEARNALEY, D.P., additional, REDDING, W.H., additional, ORMEROD, M.G., additional, SKILTON, R.A., additional, SLOANE, J.P., additional, IMRIE, S., additional, EDWARDS, P.A.W., additional, MONAGHAN, P., additional, and NEVILLE, A.M., additional

Published
1984
Full Text
View/download PDF

6. List of Authors

Author

Abe, J., primary, Addison, G.M., additional, Auböck, L., additional, Aurbach, G.D., additional, Backer, H.J., additional, Bauer, W., additional, Bélanger, L.F., additional, Bellwinkel, S., additional, Berliner, R.W., additional, Berridge, M.J., additional, Besser, G.M., additional, Bloom, S.R., additional, Blyth, C.A., additional, Blythe, W.B., additional, Boelkins, J.N., additional, Bogentoft, C., additional, Bonjour, J.-P., additional, Bordier, P.J., additional, Bossert, H., additional, Bowers, C.Y., additional, Boyle, I.T., additional, Breckenridge, A., additional, Brewer, H.B., additional, Bucheim, W., additional, Buranapong, P., additional, Burrow, G.N., additional, Bury, A.E., additional, Bussolati, G., additional, Byfield, P.G.H., additional, Cameron, D.A., additional, Cameron, J.D., additional, Capella, C., additional, Chang, J.-K., additional, Clarke, M.B., additional, Clarkson, E.M., additional, Cooper, C.W., additional, Copp, D.H., additional, Couling, I., additional, Crentzfeldt, W., additional, Currie, B.L., additional, Dacke, C.G., additional, Davies, D., additional, D'Avila, D., additional, Deftos, L.J., additional, DeLuca, H.F., additional, de Wardener, H.E., additional, Dimond, M., additional, Doherty, D., additional, Dowling, R.H., additional, Ekholm, R., additional, Ericson, L.E., additional, Feyrter, F., additional, Fleisch, H., additional, Fleming, W.R., additional, Folkers, K., additional, Foster, G.V., additional, Freedman, R.B., additional, Friedman, N., additional, Fuchs, K., additional, Galante, L., additional, Gitelman, H.J., additional, Glass, H.I., additional, Gleeson, M.H., additional, Gray, R.W., additional, Gray, T.K., additional, Greenberg, P.B., additional, Guttmann, St., additional, Habener, J.F., additional, Håkanson, R., additional, Hanson, R.C., additional, Hardman,, J.G., additional, Haroutinian, A.M., additional, Hasenjäger, M., additional, Hesch, R.-D., additional, Hill, L.F., additional, Hodgkin, D.C., additional, Holman, C.A., additional, Holst, P., additional, Horton, R., additional, Hotz, J., additional, Hüfner, M., additional, Jones, M., additional, Jullienne, A., additional, Kenny, A.D., additional, Keutmann, H.T., additional, Krook, L., additional, Kurokawa, K., additional, Lacy, P.E., additional, Lager, I., additional, Landon, J., additional, Laragh, J.H., additional, Laurence, D.J.R., additional, Le Douarin, N., additional, Le Livre, C., additional, Lequin, R.M., additional, Ljungberg, O., additional, Lumb, G.A., additional, Lundquist, I., additional, MacIntyre, I., additional, Mahgoub, A.M., additional, Martin, T.J., additional, Mason, J., additional, Matthews, E.W., additional, Mawer, E.B., additional, Mayer, G.P., additional, Melander, A., additional, Melick, R.A., additional, Milhaud, G., additional, Mills, B.G., additional, Minne, H., additional, Morgan, D.B., additional, Moseley, J.M., additional, Moukhtar, M.-S., additional, Müller, O., additional, Munson, P.L., additional, Murray, T.M., additional, Mutt, V., additional, Nathanson, B.M., additional, Neale, G., additional, Neville, A.M., additional, Newsome, F., additional, Niall, H.D., additional, Nieta, A., additional, Ng, D., additional, Nordin, B.E.C., additional, Nutbourne, D.M., additional, O'Dor, K., additional, O'Grady, R.L., additional, Omdahl, J.L., additional, Onjes, D.A., additional, Orimo, H., additional, O'Riordan, J.L.H., additional, Orme, M., additional, Otani, K., additional, Owman, Ch., additional, Parsons, J.A., additional, Paschen, K., additional, Peacock, M., additional, Pearse, A.G.E., additional, Peng, T.-C., additional, Pierides, A.M., additional, Pilczyk, R., additional, Pless, J., additional, Polak, J.M., additional, Potts, J.T., additional, Powell, D., additional, Prince, W.T., additional, Rabin, B.R., additional, Raisz, L.G., additional, Rasmussen, H., additional, Ratcliffe, J.G., additional, Ratzenhofer, M., additional, R.-Candela, J.L., additional, Reynolds, J.J., additional, Robinson, C.J., additional, Roobol, A., additional, Rudinger, J., additional, Russell, R.G.G., additional, Schenk, R., additional, Schmidt, H., additional, Schwesinger, W.H., additional, Scott, A.P., additional, Sealey, J.E., additional, Sievertsson, H., additional, Silver, J., additional, Singer, F.R., additional, Sjöberg, N.-O., additional, Smiths, R., additional, Solcia, E., additional, Spaulding, S.W., additional, Stanbury, S.W., additional, Sundler, F., additional, Sunshine, G., additional, Sutherland, E.W., additional, Tharaud, D., additional, Thompson, G.R., additional, Tregear, G.W., additional, Trummel, C.L., additional, Tun-Chot, S., additional, Van Den Berg, C.J., additional, Vassallo, G., additional, Watts, E., additional, Welsch, U., additional, Welt, L.G., additional, Williams, C., additional, Williams, D.J., additional, Winkler, K., additional, Woodhead, J.S., additional, Woodhouse, N.J.Y., additional, Yoshikawa, M., additional, Zehnder, K., additional, and Ziegler, R., additional

Published
1972
Full Text
View/download PDF

7. Cost-effectiveness of colorectal cancer screening: Comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy

Author

O'Leary, B.A., Olynyk, J.K., Neville, A.M., Platell, C.F., O'Leary, B.A., Olynyk, J.K., Neville, A.M., and Platell, C.F.

Abstract

Background and Aims: To determine the cost-effectiveness of screening for colorectal cancer using flexible sigmoidoscopy once every 10 years, compared with annual and biennial rehydrated Hemoccult fecal occult blood testing and colonoscopy once every 10 years, or no screening. Methods: A Markov model was developed in order to simulate the progression of a cohort of asymptomatic, average-risk individuals aged 55–64 years who were moving through a defined series of states towards death. The main outcome measures were: cases of colorectal cancer averted, colorectal cancer deaths averted, and cost per life-year saved. Results: Colonoscopy averted the greatest number of cases of colorectal cancer (35%), followed by flexible sigmoidoscopy (25%), and annual (24%) and biennial (14%) fecal occult blood testing. Colonoscopy averted the greatest number of deaths from colorectal cancer (31%), followed by annual fecal occult blood testing (29%), flexible sigmoidoscopy (21%) and biennial fecal occult blood testing (19%). Flexible sigmoidoscopy was the most efficient in terms of cost per life-year saved (A$16 801), followed by colonoscopy (A$19 285), biennial (A$41 183), and annual (A$46 900) fecal occult blood testing. Conclusions: Flexible sigmoidoscopy and colonoscopy are cost-effective strategies for reducing the disease burden of colorectal cancer.

Published
2004

12. Immunohistochemical localization of CD1a-positive putative dendritic cells in human breast tumours.

Author

Hillenbrand, E.E., Neville, A.M., and Coventry, B.J.

Subjects
*BREAST cancer research, *CANCER diagnosis, *METASTASIS, *CELL morphology
Abstract

The presence of a high number of infiltrating CD1a+cells in malignant neoplasms has been reported to be associated with an improved prognosis, reduced tumour recurrence and fewer metastases. This study identified a population of CD1a+cells within the lymphoid cell infiltrate in human ductal breast carcinoma (n= 52), which was significantly different from normal breast tissue, in which only two out of nine cases expressed CD1a+cells (P= 0.0192). In the majority of cases, the infiltrate was low compared with the number of macrophages and T cells present (results not shown). There was no correlation between the number of CD1a+cells and tumour grade, with all tumour grades expressing similar numbers of infiltrating CD1a+cells. There was clear evidence, however, that the CD1a+cells were closely associated with tumour cells. It is likely that CD1a+cells have a role in antigen capture and presentation in human tumours, and this study documents the density of CD1a+cells in a large sample of all histological grades of human breast carcinomas. 1999 Cancer Research Campaign [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

15. TREATMENT OF DISSEMINATED BREAST CANCER WITH TAMOXIFEN, AMINOGLUTETHIMIDE, HYDROCORTISONE, AND DANAZOL, USED IN COMBINATION OR SEQUENTIALLY

Author

Powles, T.J, Ford, H.T, Nash, A.G, Ashley, S, Gazet, J.C, Neville, A.M, and Coombes, R.C

Abstract

222 patients with disseminated breast cancer have been randomised to receive either a combination of hormone therapies using tamoxifen, aminoglutethimide with hydrocortisone, and danazol (TAD), or tamoxifen alone. The response to the combination was significantly better (43%) than that to tamoxifen alone (31%). Patients who relapsed after response or failed to respond to tamoxifen were subsequently treated with aminoglutethimide and then, if possible, with danazol. Some patients who received TAD were subsequently treated with alternative endocrine therapy, which was usually medroxyprogesterone acetate. Of the 111 patients who initially received tamoxifen, 43 responded to the tamoxifen and/or subsequent endocrine therapy. Of the 111 patients who initially received TAD, 50 responded. Although the duration of response to TAD was the same as for tamoxifen, the TAD patients achieved remission more quickly. The total time in endocrine remission for patients receiving TAD is 303 months to date, compared with 264 months for patients receiving tamoxifen. Survival for patients randomised to receive TAD or tamoxifen is the same.

Published
1984
Full Text
View/download PDF

16. Secretion of immunoreactive calcitonin by human breast carcinomas.

Author

Coombes, R.C., Easty, G.C., Detre, S.I., Hillyard, C.J., Stevens, U., Girgis, S.I., Galante, L.S., Heywood, L., Macintyre, I., and Neville, A.M.

Subjects
CALCITONIN, BREAST cancer diagnosis, SECRETION
Abstract

Investigates the level of secretion of immunoreactive calcitonin by human breast carcinomas. Increase of levels in plasma calcitonin; Maintenance of monolayer cultures of breast carcinoma; Indication of calcitonin in breast carcinomas; Benefits of calcitonin measurement in staging patients.

Published
1975
Full Text
View/download PDF

21. Paper 1. Concrete - a non-elastic material in the laboratory and in structures. Paper 2. Design of concrete structures for creep. Paper 3. Comments on the education and training of civil engineers in English-speaking countries

Author

Neville, A.M.

Abstract

Two of the lectures are technical in nature, the other one of more general interest. The lecture on non-elastic features of concrete considers the fundamental issues of elastic and non-elastic design of structures, gives the reasons for the use of elastic methods but points out that local non-elasticity is a condition which must be satisfied. A brief mention of non-elastic methods is made but the topic of design for creep forms the subject matter of the second technical lecture. The lecture on non-elasticity further considers the stress-strain relation in concrete and reviews the various definitions of the modulus of elasticity and the methods of its determination. The influence of the rate of application of load is mentioned. Data on the variation in the modulus within structures are presented. Behaviour of concrete under cyclic loading is considered with especial reference to deformation: the changes in the shape of the stress-strain curve on loading and unloading and the resultant variation in the area of the hysteresis loop of the stress-strain relation are described. The elastic and non-elastic strain at failure are considered as an evaluation of fatigue life. Creep under static and cyclic loading is compared, and data on the influence of the amplitude and mean value of a cyclic stress on creep are presented. The lecture on creep design first justifies the need for consideration of creep in design of reinforced and prestressed concrete structures of various types. Shrinkage and creep, including its basic and drying components, are defined. Creep buckling is defined, and the time-dependent variation in the moment-deflection relation in reinforced concrete columns is considered. Hence, a method of prediction of life under a sustained load is described. The fundamental equation for the rate of creep approach to the solution of deformation problems involving load increments applied at various ages is presented. The relaxation coefficient is then introduced to account for the effect of ageing on the ultimate value of creep for stress increments applied at various ages; thus the change in stress due to creep and the associated relaxation of stress by creep are allowed for. The influence of reinforcement is taken into account by a stiffness coefficient which reflects both the amount and position of the steel. Using this approach, the strain in a member under various conditions of shrinkage and load can be expressed, and the method is extended to cracked beams. Prestressed concrete, both pretensioned and post-tensioned, is also considered. The application of the method to continuous beams with sinking supports is also mentioned. The third and last lecture is concerned with education and training of civil engineers, mainly in England, but brief comments on other Commonwealth countries and on the U.S. are made. The essential features of the British system are emphasized and the way in which slow changes are made is mentioned. The lecture also raises the more fundamental question of purposes of university education, and reviews the relevance of a university course to future employment.

Published
1972

23. Cancer-testis antigen expression in triple-negative breast cancer

Author

Curigliano, G., Viale, G., Ghioni, M., Jungbluth, A. A., Bagnardi, V., Spagnoli, G. C., Neville, A.M., Nolè, F., Rotmensz, N., Goldhirsch, A., Curigliano, G., Viale, G., Ghioni, M., Jungbluth, A. A., Bagnardi, V., Spagnoli, G. C., Neville, A.M., Nolè, F., Rotmensz, N., and Goldhirsch, A.

Abstract

Background: Cancer-testis (CT) antigens, frequently expressed in human germline cells but not in somatic tissues, may become aberrantly reexpressed in different cancer types. The aim of this study was to investigate the expression of CT antigens in breast cancer. Patients and methods: A total of 100 selected invasive breast cancers, including 50 estrogen receptor (ER) positive/HER2 negative and 50 triple negative (TN), were examined for NY-ESO-1 and MAGE-A expression by immunohistochemistry. Results: A significantly higher expression of MAGE-A and NY-ESO-1 was detected in TN breast cancers compared with ER-positive tumors (P = 0.04). MAGE-A expression was detected in 13 (26%) TN cancers compared with 5 (10%) ER-positive tumors (P = 0.07). NY-ESO-1 expression was confirmed in nine (18%) TN tumor samples compared with two (4%) ER-positive tumors. Conclusions: MAGE-A and NY-ESO-1 CT antigens are expressed in a substantial proportion of TN breast cancers. Because of the limited therapeutic options for this group of patients, CT antigen-based vaccines might prove to be useful for patients with this phenotype of breast cancer

40. RADIOLABELLED ANTIBODY FOR LOCALISING METASTASES

Author

Anderson, P., primary, Bradwell, A.R., additional, Keeling, A.A., additional, Dykes, P.W., additional, Britton, K.E., additional, Granowska, M., additional, Mather, S.J., additional, Rainsbury, R.M., additional, Coombes, R.C., additional, Westwood, J.H., additional, Neville, A.M., additional, Haisma, H., additional, Hilkens, J., additional, and Goedemans, W., additional

Published
1983
Full Text
View/download PDF

50. Prognostic importance of occult lymph node metastases in patients with breast cancer

Author

Cote, R., Chaiwun, B., Ou, J., Taylor, C., Peterson, H., Belber, R., Goldhirsch, A., and Neville, A.M.

Subjects
Lymphatic metastasis -- Research, Breast cancer -- Prognosis, Health, Science and technology
Abstract

AUTHORS: R. Cote, B. Chaiwun, J. Ou, C. Taylor, H. Peterson, R. Belber, A. Goldhirsch and A.M. Neville. University of Southern California School of Medicine at Los Angeles and the [...]

Published
1992

Catalog

Books, media, physical & digital resources
See catalog results